{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:09:29Z","timestamp":1786115369618,"version":"build-2736575974"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007414","name":"Qassim University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05214-7","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:37:05Z","timestamp":1780418225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Resistance pathways and next-generation treatments in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"17","author":[{"given":"Rawane","family":"Bellemrrabet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezzahra","family":"Rachid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Lahmouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Aboussaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Al Abdulmonem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhakim","family":"Bouyahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oualid","family":"Abboussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loubna","family":"Amahdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"7","key":"5214_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBDO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"issue":"5","key":"5214_CR2","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s12185-019-02788-7","volume":"111","author":"Y Kikushige","year":"2020","unstructured":"Kikushige Y. Pathophysiology of chronic lymphocytic leukemia and human B1 cell development. Int J Hematol. 2020;111(5):634\u201341. https:\/\/doi.org\/10.1007\/s12185-019-02788-7.","journal-title":"Int J Hematol"},{"issue":"20","key":"5214_CR3","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1158\/1078-0432.CCR-21-0701","volume":"27","author":"R Bomben","year":"2021","unstructured":"Bomben R, Rossi FM, Vit F, Bittolo T, D\u2019Agaro T, Zucchetto A, et al. TP53 mutations with low variant allele frequency predict short survival in chronic lymphocytic leukemia. Clin Cancer Res. 2021;27(20):5566\u201375. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0701.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5214_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.35754\/0234-5730-2022-67-1-75-89","volume":"67","author":"TN Obukhova","year":"2022","unstructured":"Obukhova TN, Kislova MI, Nikitin EA, Kislitsyna MA, Biderman BV, Tagirova MK, et al. Structure and prognostic signifi cance of 13q14 deletion in chronic lymphocytic leukemia. Ross Zh Gematol Transfuziol. 2022;67(1):75\u201389. https:\/\/doi.org\/10.35754\/0234-5730-2022-67-1-75-89.","journal-title":"Ross Zh Gematol Transfuziol"},{"issue":"6","key":"5214_CR5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41591-018-0028-4","volume":"24","author":"R Beekman","year":"2018","unstructured":"Beekman R, Chapaprieta V, Russi\u00f1ol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, et al. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. 2018;24(6):868\u201380. https:\/\/doi.org\/10.1038\/s41591-018-0028-4.","journal-title":"Nat Med"},{"issue":"9","key":"5214_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/genes16091064","volume":"16","author":"S Sekeres","year":"2025","unstructured":"Sekeres S, Lamkin EN, Bravo E, Cool A, Taylor J. Resistance mutations in CLL: Genetic mechanisms shaping the future of targeted therapy. Genes. 2025;16(9):1064. https:\/\/doi.org\/10.3390\/genes16091064.","journal-title":"Genes"},{"issue":"5","key":"5214_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hon.2933","volume":"39","author":"H Wang","year":"2021","unstructured":"Wang H, Zhang W, Yang J, Zhou K. The resistance mechanisms and treatment strategies of BTK inhibitors in b-cell lymphoma. Hematol Oncol. 2021;39(5):605\u201315. https:\/\/doi.org\/10.1002\/hon.2933.","journal-title":"Hematol Oncol"},{"issue":"6","key":"5214_CR8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.revmed.2022.01.010","volume":"43","author":"M Gauthier","year":"2022","unstructured":"Gauthier M. La leuc\u00e9mie lympho\u00efde chronique. Rev Med Interne. 2022;43(6):356\u201364. https:\/\/doi.org\/10.1016\/j.revmed.2022.01.010.","journal-title":"Rev Med Interne"},{"issue":"3","key":"5214_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111115","volume":"40","author":"CL Chiang","year":"2022","unstructured":"Chiang CL, Hu EY, Chang L, Labanowska J, Zapolnik K, Mo X, et al. Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity. Cell Rep. 2022;40(3):111115. https:\/\/doi.org\/10.1016\/j.celrep.2022.111115.","journal-title":"Cell Rep"},{"issue":"1","key":"5214_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/1878-0261.12416","volume":"13","author":"V Spina","year":"2019","unstructured":"Spina V, Rossi D. Overview of non-coding mutations in chronic lymphocytic leukemia. Mol Oncol. 2019;13(1):99\u2013106. https:\/\/doi.org\/10.1002\/1878-0261.12416.","journal-title":"Mol Oncol"},{"issue":"11","key":"5214_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918. https:\/\/doi.org\/10.1001\/jama.2023.1946.","journal-title":"JAMA"},{"key":"5214_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.70010","author":"RK Wood","year":"2026","unstructured":"Wood RK, Elsharawi I, Goudie M, Bruy\u00e8re H, Rahmani M, Gillan TL. The ABCs of IGHV testing in chronic lymphocytic leukaemia: current recommendations, ongoing challenges, and future directions. Int J Lab Hematol. 2026. https:\/\/doi.org\/10.1111\/ijlh.70010.","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"5214_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0893-0","volume":"22","author":"K Milne","year":"2020","unstructured":"Milne K, Sturrock B, Chevassut T. Chronic lymphocytic leukaemia in 2020: the future has arrived. Curr Oncol Rep. 2020;22(4):36. https:\/\/doi.org\/10.1007\/s11912-020-0893-0.","journal-title":"Curr Oncol Rep"},{"issue":"17","key":"5214_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179337","volume":"22","author":"A Pacholewska","year":"2021","unstructured":"Pacholewska A, Grimm C, Herling CD, Lienhard M, K\u00f6nigs A, Timmermann B, et al. Altered DNA methylation profiles in SF3B1 mutated CLL patients. Int J Mol Sci. 2021;22(17):9337. https:\/\/doi.org\/10.3390\/ijms22179337.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5214_CR15","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.3324\/haematol.2020.261891","volume":"106","author":"F Pozzo","year":"2020","unstructured":"Pozzo F, Bittolo T, Tissino E, Vit F, Vendramini E, Laurenti L, et al. SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. Haematologica. 2020;106(12):3125\u201335. https:\/\/doi.org\/10.3324\/haematol.2020.261891.","journal-title":"Haematologica"},{"issue":"16","key":"5214_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163735","volume":"10","author":"M Putowski","year":"2021","unstructured":"Putowski M, Giannopoulos K. Perspectives on precision medicine in chronic lymphocytic leukemia: targeting recurrent mutations\u2014NOTCH1, SF3B1, MYD88, BIRC3. J Clin Med. 2021;10(16):3735. https:\/\/doi.org\/10.3390\/jcm10163735.","journal-title":"J Clin Med"},{"issue":"12","key":"5214_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122997","volume":"14","author":"F Pozzo","year":"2022","unstructured":"Pozzo F, Bittolo T, Tissino E, Zucchetto A, Bomben R, Polcik L, et al. Multiple mechanisms of NOTCH1 activation in chronic lymphocytic leukemia: NOTCH1 mutations and beyond. Cancers. 2022;14(12):2997. https:\/\/doi.org\/10.3390\/cancers14122997.","journal-title":"Cancers"},{"issue":"5","key":"5214_CR18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/ng.2584","volume":"45","author":"AJ Ramsay","year":"2013","unstructured":"Ramsay AJ, Quesada V, Foronda M, Conde L, Mart\u00ednez-Trillos A, Villamor N, et al. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nat Genet. 2013;45(5):526\u201330. https:\/\/doi.org\/10.1038\/ng.2584.","journal-title":"Nat Genet"},{"issue":"1","key":"5214_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood-2014-07-589069","volume":"125","author":"V Audrito","year":"2015","unstructured":"Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood. 2015;125(1):111\u201323. https:\/\/doi.org\/10.1182\/blood-2014-07-589069.","journal-title":"Blood"},{"issue":"1","key":"5214_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11938","volume":"7","author":"AF Rendeiro","year":"2016","unstructured":"Rendeiro AF, Schmidl C, Strefford JC, Walewska R, Davis Z, Farlik M, et al. Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. Nat Commun. 2016;7(1):11938. https:\/\/doi.org\/10.1038\/ncomms11938.","journal-title":"Nat Commun"},{"key":"5214_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pathmechdis-012419-032810","volume":"15","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Diaz-Navarro A, Delgado J, Puente XS, Campo E. Genomic and epigenomic alterations in chronic lymphocytic leukemia. Annu Rev Pathol Mech Dis. 2020;15:149\u201377. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012419-032810.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"15","key":"5214_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153856","volume":"13","author":"C Vitale","year":"2021","unstructured":"Vitale C, Boccellato E, Comba L, Jones R, Perutelli F, Griggio V, et al. Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia. Cancers. 2021;13(15):3856. https:\/\/doi.org\/10.3390\/cancers13153856.","journal-title":"Cancers"},{"issue":"2","key":"5214_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020217","volume":"10","author":"S Fiorcari","year":"2021","unstructured":"Fiorcari S, Maffei R, Atene CG, Potenza L, Luppi M, Marasca R. Nurse-like cells and chronic lymphocytic leukemia B cells: a mutualistic crosstalk inside tissue microenvironments. Cells. 2021;10(2):217. https:\/\/doi.org\/10.3390\/cells10020217.","journal-title":"Cells"},{"issue":"3","key":"5214_CR24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3324\/haematol.2016.151100","volume":"102","author":"M Palma","year":"2017","unstructured":"Palma M, Gentilcore G, Heimersson K, Mozaffari F, N\u00e4sman-Glaser B, Young E, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102(3):562\u201372. https:\/\/doi.org\/10.3324\/haematol.2016.151100.","journal-title":"Haematologica"},{"key":"5214_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.594782","author":"M B\u00f6ttcher","year":"2020","unstructured":"B\u00f6ttcher M, Baur R, Stoll A, Mackensen A, Mougiakakos D. Linking immunoevasion and metabolic reprogramming in B-cell\u2013derived lymphomas. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.594782.","journal-title":"Front Oncol"},{"issue":"1","key":"5214_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00292-z","volume":"11","author":"Y Nie","year":"2022","unstructured":"Nie Y, Yun X, Zhang Y, Wang X. Targeting metabolic reprogramming in chronic lymphocytic leukemia. Exp Hematol Oncol. 2022;11(1):39. https:\/\/doi.org\/10.1186\/s40164-022-00292-z.","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"5214_CR27","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","volume":"105","author":"J Delgado","year":"2020","unstructured":"Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica. 2020;105(9):2205\u201317. https:\/\/doi.org\/10.3324\/haematol.2019.236000.","journal-title":"Haematologica"},{"key":"5214_CR28","doi-asserted-by":"publisher","unstructured":"Pan Y. The Diseases of Hematopoietic and Lymphoid Systems. In: Chen K, Liang L, Li M, Pan Y, \u00e9diteurs, editors. Textbook of Pathologic Anatomy: For Medical Students [Internet]. Singapore: Springer Nature; 2024. pp. 317\u201342. [cit\u00e9 23 janv 2026]. https:\/\/doi.org\/10.1007\/978-981-99-8445-9_10. Disponible sur.","DOI":"10.1007\/978-981-99-8445-9_10"},{"issue":"2","key":"5214_CR29","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06791.x","volume":"139","author":"TD Shanafelt","year":"2007","unstructured":"Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, et al. Quality of life in chronic lymphocytic leukemia: An international survey of 1482 patients. Br J Haematol. 2007;139(2):255\u201364. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06791.x.","journal-title":"Br J Haematol"},{"issue":"11","key":"5214_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00756-9","volume":"12","author":"PJ Hampel","year":"2022","unstructured":"Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022;12(11):161. https:\/\/doi.org\/10.1038\/s41408-022-00756-9.","journal-title":"Blood Cancer J"},{"issue":"12","key":"5214_CR31","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1002\/ajh.26367","volume":"96","author":"M Hallek","year":"2021","unstructured":"Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679\u2013705. https:\/\/doi.org\/10.1002\/ajh.26367.","journal-title":"Am J Hematol"},{"issue":"11","key":"5214_CR32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2146\/ajhp140282","volume":"72","author":"GW Jean","year":"2015","unstructured":"Jean GW, Comeau JM. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia. Am J Health Syst Pharm. 2015;72(11):933\u201342. https:\/\/doi.org\/10.2146\/ajhp140282.","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"5214_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001235","volume":"8","author":"SS Neelapu","year":"2020","unstructured":"Neelapu SS, Adkins S, Ansell SM, Brody J, Cairo MS, Friedberg JW, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer. 2020;8(2):e001235. https:\/\/doi.org\/10.1136\/jitc-2020-001235.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"5214_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-018-0001-1","volume":"24","author":"G Ferrer","year":"2018","unstructured":"Ferrer G, Montserrat E. Critical molecular pathways in CLL therapy. Mol Med. 2018;24(1):9. https:\/\/doi.org\/10.1186\/s10020-018-0001-1.","journal-title":"Mol Med"},{"issue":"2","key":"5214_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bulcan.2015.12.003","volume":"103","author":"A Doug\u00e9","year":"2016","unstructured":"Doug\u00e9 A, Ravinet A, Bay JO, Tournilhac O, Gui\u00e8ze R, Lemal R. [Ibrutinib prescription in B-cell lymphoid neoplasms]. Bull Cancer (Paris). 2016;103(2):127\u201337. https:\/\/doi.org\/10.1016\/j.bulcan.2015.12.003.","journal-title":"Bull Cancer (Paris)"},{"issue":"7","key":"5214_CR36","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1007\/s12325-021-01991-5","volume":"39","author":"Q Huang","year":"2022","unstructured":"Huang Q, Deering KL, Harshaw Q, Leslie LA. Real-world clinical outcomes of first-line Ibrutinib or chemoimmunotherapy in patients with chronic lymphocytic leukemia by risk status. Adv Ther. 2022;39(7):3292\u2013307. https:\/\/doi.org\/10.1007\/s12325-021-01991-5.","journal-title":"Adv Ther"},{"issue":"9","key":"5214_CR37","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","volume":"8","author":"C Tam","year":"2024","unstructured":"Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8(9):2300\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023012221.","journal-title":"Blood Adv"},{"issue":"6","key":"5214_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2023.101538","volume":"14","author":"PC Johnson","year":"2023","unstructured":"Johnson PC, Woyach JA, Ulrich A, Marcotte V, Nipp RD, Lage DE, et al. Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. J Geriatr Oncol. 2023;14(6):101538. https:\/\/doi.org\/10.1016\/j.jgo.2023.101538.","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"5214_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2300696.","journal-title":"N Engl J Med"},{"issue":"5","key":"5214_CR40","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1182\/bloodadvances.2024014474","volume":"9","author":"JD Soumerai","year":"2024","unstructured":"Soumerai JD, Barrientos J, Ahn I, Coombs C, Gladstone D, Hoffman M, et al. Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL. Blood Adv. 2024;9(5):1213\u201329. https:\/\/doi.org\/10.1182\/bloodadvances.2024014474.","journal-title":"Blood Adv"},{"key":"5214_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7050","author":"BR LaPlant","year":"2024","unstructured":"LaPlant BR, Parikh SA, Leis JF, Call TG, Shanafelt TD, He R, et al. Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL). J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7050.","journal-title":"J Clin Oncol"},{"issue":"5","key":"5214_CR42","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/17425255.2019.1606211","volume":"15","author":"A Korycka-Wolowiec","year":"2019","unstructured":"Korycka-Wolowiec A, Wolowiec D, Kubiak-Mlonka A, Robak T. Venetoclax in the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2019;15(5):353\u201366. https:\/\/doi.org\/10.1080\/17425255.2019.1606211.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"13","key":"5214_CR43","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138(13):1120\u201336. https:\/\/doi.org\/10.1182\/blood.2020006785.","journal-title":"Blood"},{"issue":"N\u00b0 Supp 1","key":"5214_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1684\/hma.2024.1837","volume":"30","author":"MS Dilhuydy","year":"2024","unstructured":"Dilhuydy MS. Crit\u00e8res influen\u00e7ant la prise en charge en premi\u00e8re ligne dans la leuc\u00e9mie lympho\u00efde chronique. H\u00e9matologie. 2024;30(N\u00b0 Supp 1):13\u20138. https:\/\/doi.org\/10.1684\/hma.2024.1837.","journal-title":"H\u00e9matologie"},{"key":"5214_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100921","author":"N Maher","year":"2025","unstructured":"Maher N, Gaidano G. Ramping up the express stairs: Lisaftoclax in CLL. Med. 2025. https:\/\/doi.org\/10.1016\/j.medj.2025.100921.","journal-title":"Med"},{"issue":"1","key":"5214_CR46","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.045","volume":"16","author":"U Testa","year":"2024","unstructured":"Testa U, Pelosi E, Castelli G, Fresa A, Laurenti L. CAR-T cells in chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis. 2024;16(1):e2024045. https:\/\/doi.org\/10.4084\/MJHID.2024.045.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"5214_CR47","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1182\/hematology.2024000570","volume":"2024","author":"AP Kater","year":"2024","unstructured":"Kater AP, Siddiqi T. Relapsed\/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers. Hematol Am Soc Hematol Educ Program. 2024;2024(1):474\u201381. https:\/\/doi.org\/10.1182\/hematology.2024000570.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"5214_CR48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor Ibrutinib. N Engl J Med. 2014. https:\/\/doi.org\/10.1056\/NEJMoa1400029.","journal-title":"N Engl J Med"},{"issue":"1","key":"5214_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589","volume":"7","author":"JA Burger","year":"2016","unstructured":"Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7(1):11589. https:\/\/doi.org\/10.1038\/ncomms11589.","journal-title":"Nat Commun"},{"issue":"7","key":"5214_CR50","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1182\/blood.2019000854","volume":"134","author":"A Quinquenel","year":"2019","unstructured":"Quinquenel A, Fornecker LM, Letestu R, Ysebaert L, Fleury C, Lazarian G, et al. Pr\u00e9valence des mutations BTK et PLCG2 dans une cohorte r\u00e9elle de patients atteints de LLC toujours sous ibrutinib apr\u00e8s 3 ans: une \u00e9tude du groupe FILO. Blood. 2019;134(7):641\u20134. https:\/\/doi.org\/10.1182\/blood.2019000854.","journal-title":"Blood"},{"issue":"14","key":"5214_CR51","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","volume":"1","author":"KD Jayappa","year":"2017","unstructured":"Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933\u201346. https:\/\/doi.org\/10.1182\/bloodadvances.2016004176.","journal-title":"Blood Adv"},{"issue":"N\u00b0 Supp 3","key":"5214_CR52","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1684\/hma.2020.1564","volume":"26","author":"R Gui\u00e8ze","year":"2020","unstructured":"Gui\u00e8ze R. M\u00e9canismes de r\u00e9sistance aux th\u00e9rapies cibl\u00e9es. H\u00e9matologie. 2020;26(N\u00b0 Supp 3):20\u20136. https:\/\/doi.org\/10.1684\/hma.2020.1564.","journal-title":"H\u00e9matologie"},{"issue":"3","key":"5214_CR53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/j.seminhematol.2024.03.003","volume":"261","author":"SS Chen","year":"2024","unstructured":"Chen SS. Mod\u00e8les murins de LLC\u202f: Mod\u00e9lisation in vivo de l\u2019initiation, de la progression et de la transformation de la maladie. Semin Hematol. 2024;261(3):201\u20137. https:\/\/doi.org\/10.1053\/j.seminhematol.2024.03.003.","journal-title":"Semin Hematol"},{"issue":"6","key":"5214_CR54","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2018881029","volume":"134","author":"A Scheffold","year":"2019","unstructured":"Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, et al. IGF1R as druggable target mediating PI3K-\u03b4 inhibitor resistance in a murine model of chronic lymphocytic leukemia. Blood. 2019;134(6):534\u201347. https:\/\/doi.org\/10.1182\/blood.2018881029.","journal-title":"Blood"},{"issue":"20","key":"5214_CR55","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1002\/1873-3468.15079","volume":"599","author":"M Buchner","year":"2025","unstructured":"Buchner M. Insights into PI3K \/ AKT signaling in B cell development and chronic lymphocytic leukemia. FEBS Lett. 2025;599(20):2896\u2013910. https:\/\/doi.org\/10.1002\/1873-3468.15079.","journal-title":"FEBS Lett"},{"issue":"3","key":"5214_CR56","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to Venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9(3):342\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1119.","journal-title":"Cancer Discov"},{"issue":"8","key":"5214_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02867-2","volume":"11","author":"A Roca-Portoles","year":"2020","unstructured":"Roca-Portoles A, Rodriguez-Blanco G, Sumpton D, Cloix C, Mullin M, Mackay GM, et al. Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death Dis. 2020;11(8):616. https:\/\/doi.org\/10.1038\/s41419-020-02867-2.","journal-title":"Cell Death Dis"},{"key":"5214_CR58","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/978-3-31989512-3_18","volume":"1066","author":"AC McCarter","year":"2018","unstructured":"McCarter AC, Wang Q, Chiang M. Notch in Leukemia. Adv Exp Med Biol. 2018;1066:355\u201394. https:\/\/doi.org\/10.1007\/978-3-31989512-3_18.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"5214_CR59","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/leu.2017.296","volume":"32","author":"D Benedetti","year":"2018","unstructured":"Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, et al. NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-\u03ba B pathways. Leukemia. 2018;32(3):654\u201362. https:\/\/doi.org\/10.1038\/leu.2017.296.","journal-title":"Leukemia"},{"issue":"4","key":"5214_CR60","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood-2008-02-139725","volume":"113","author":"E Rosati","year":"2009","unstructured":"Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113(4):856\u201365. https:\/\/doi.org\/10.1182\/blood-2008-02-139725.","journal-title":"Blood"},{"issue":"22","key":"5214_CR61","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1182\/blood.2020006701","volume":"137","author":"D Tardivon","year":"2021","unstructured":"Tardivon D, Antoszewski M, Zangger N, Nkosi M, Sordet-Dessimoz J, Hendriks R, et al. Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia. Blood. 2021;137(22):3079\u201392. https:\/\/doi.org\/10.1182\/blood.2020006701.","journal-title":"Blood"},{"issue":"16","key":"5214_CR62","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1182\/blood.2025028529","volume":"146","author":"M Guo","year":"2025","unstructured":"Guo M, Memis T, Ehrmann AS, Pittrof A, Baumann B, Ferrante F, et al. A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL. Blood. 2025;146(16):1936\u201349. https:\/\/doi.org\/10.1182\/blood.2025028529.","journal-title":"Blood"},{"issue":"4","key":"5214_CR63","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/bjh.19604","volume":"205","author":"MY Gao","year":"2024","unstructured":"Gao MY, Georgiou A, Lin VS, Jahja M, White CA, Anderson MA, et al. Potential impact of NOTCH1 activation on Venetoclax sensitivity in chronic lymphocytic leukaemia: in vitro insights and clinical implications. Br J Haematol. 2024;205(4):1389\u201394. https:\/\/doi.org\/10.1111\/bjh.19604.","journal-title":"Br J Haematol"},{"issue":"1","key":"5214_CR64","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000533610","volume":"147","author":"S Koehrer","year":"2024","unstructured":"Koehrer S, Burger JA. Chronic lymphocytic leukemia: disease biology. Acta Haematol. 2024;147(1):8\u201321 (doi:10.1159\/000533610IF: 1.1 Q4 B4 PubMed PMID: 37717577IF: 1.1 Q4 B4; PubMed Central PMCID: PMC11753505IF: 1.1 Q4 B4).","journal-title":"Acta Haematol"},{"issue":"6","key":"5214_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061396","volume":"12","author":"DG Efremov","year":"2020","unstructured":"Efremov DG, Turkalj S, Laurenti L. Mechanisms of B cell receptor activation and responses to B cell receptor inhibitors in B cell malignancies. Cancers Basel. 2020;12(6):1396. https:\/\/doi.org\/10.3390\/cancers12061396.","journal-title":"Cancers Basel"},{"issue":"6","key":"5214_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061571","volume":"14","author":"I Hus","year":"2022","unstructured":"Hus I, Pu\u0142a B, Robak T. PI3K inhibitors for the treatment of chronic lymphocytic leukemia: current status and future perspectives. Cancers Basel. 2022;14(6):1571. https:\/\/doi.org\/10.3390\/cancers14061571.","journal-title":"Cancers Basel"},{"issue":"9","key":"5214_CR67","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","volume":"8","author":"C Tam","year":"2024","unstructured":"Tam C, Thompson PA. BTK inhibitors in CLL: second-generation drugs and beyond. Blood Adv. 2024;8(9):2300\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023012221.","journal-title":"Blood Adv"},{"issue":"7","key":"5214_CR68","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2174\/156800910793605794","volume":"10","author":"RK Gandhirajan","year":"2010","unstructured":"Gandhirajan RK, Poll-Wolbeck SJ, Gehrke I, Kreuzer KA. Wnt\/\u03b2-catenin\/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options. Curr Cancer Drug Targets. 2010;10(7):716\u201327. https:\/\/doi.org\/10.2174\/156800910793605794.","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"5214_CR69","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.14312","volume":"175","author":"L Poppova","year":"2016","unstructured":"Poppova L, Janovska P, Plevova K, Radova L, Plesingerova H, Borsky M, et al. Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. Br J Haematol. 2016;175(5):851\u20139. https:\/\/doi.org\/10.1111\/bjh.14312.","journal-title":"Br J Haematol"},{"issue":"19","key":"5214_CR70","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2009-03-206482","volume":"114","author":"S Sharma","year":"2009","unstructured":"Sharma S, Lichtenstein A. Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells. Blood. 2009;114(19):4179\u201385. https:\/\/doi.org\/10.1182\/blood-2009-03-206482.","journal-title":"Blood"},{"issue":"24","key":"5214_CR71","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1111\/bph.13949","volume":"174","author":"P Janovsk\u00e1","year":"2017","unstructured":"Janovsk\u00e1 P, Bryja V. Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas. Br J Pharmacol. 2017;174(24):4701\u201315. https:\/\/doi.org\/10.1111\/bph.13949.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"5214_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01032-2","volume":"14","author":"JS Walker","year":"2021","unstructured":"Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, et al. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. J Hematol Oncol. 2021;14(1):17. https:\/\/doi.org\/10.1186\/s13045-021-01032-2.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"5214_CR73","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-21-3867","volume":"28","author":"DM Stephens","year":"2022","unstructured":"Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, et al. Selinexor combined with Ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: a phase I study. Clin Cancer Res. 2022;28(15):3242\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3867.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5214_CR74","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3324\/haematol.2023.283372","volume":"109","author":"DW Woolston","year":"2024","unstructured":"Woolston DW, Lee ND, Shadman M, Latorre-Esteves E, Tee XR, Fredrickson J, et al. Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies. Haematologica. 2024;109(3):835\u201345. https:\/\/doi.org\/10.3324\/haematol.2023.283372.","journal-title":"Haematologica"},{"issue":"9","key":"5214_CR75","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41375-025-02662","volume":"39","author":"P Blombery","year":"2025","unstructured":"Blombery P, Chatzikonstantinou T, Gerousi M, Rosenquist R, Gaidano G, Pospisilova S, et al. Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice. Leukemia. 2025;39(9):2049\u201360. https:\/\/doi.org\/10.1038\/s41375-025-02662.","journal-title":"Leukemia"},{"issue":"8","key":"5214_CR76","doi-asserted-by":"publisher","first-page":"e10855","DOI":"10.15252\/msb.202110855","volume":"18","author":"PM Bruch","year":"2022","unstructured":"Bruch PM, Giles HA, Kolb C, Herbst SA, Becirovic T, Roider T, et al. Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL. Mol Syst Biol. 2022;18(8):e10855. https:\/\/doi.org\/10.15252\/msb.202110855.","journal-title":"Mol Syst Biol"},{"issue":"12","key":"5214_CR77","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/stmcls\/sxae060","volume":"42","author":"SJ Sonnentag","year":"2024","unstructured":"Sonnentag SJ, Ibrahim NSM, Orian-Rousseau V. CD44: a stemness driver, regulator, and marker-all in one? Stem Cells. 2024;42(12):1031\u20139. https:\/\/doi.org\/10.1093\/stmcls\/sxae060.","journal-title":"Stem Cells"},{"issue":"20","key":"5214_CR78","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.1182\/blood-2012-11-466250","volume":"121","author":"O Fedorchenko","year":"2013","unstructured":"Fedorchenko O, Stiefelhagen M, Peer-Zada AA, Barthel R, Mayer P, Eckei L, et al. CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemia. Blood. 2013;121(20):4126\u201336. https:\/\/doi.org\/10.1182\/blood-2012-11-466250.","journal-title":"Blood"},{"issue":"10","key":"5214_CR79","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood.2024026672","volume":"145","author":"CS Tam","year":"2025","unstructured":"Tam CS, Balendran S, Blombery P. Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors. Blood. 2025;145(10):1005\u20139. https:\/\/doi.org\/10.1182\/blood.2024026672.","journal-title":"Blood"},{"issue":"20","key":"5214_CR80","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood.2022017341","volume":"140","author":"A Condoluci","year":"2022","unstructured":"Condoluci A, Rossi D. Mechanisms of resistance to venetoclax. Blood. 2022;140(20):2094\u20136. https:\/\/doi.org\/10.1182\/blood.2022017341.","journal-title":"Blood"},{"issue":"1","key":"5214_CR81","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3324\/haematol.2023.282760","volume":"109","author":"Z Chen","year":"2023","unstructured":"Chen Z, Cretenet G, Carnazzo V, Simon-Molas H, Kater AP, van der Windt GJW, et al. Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia. Haematologica. 2023;109(1):151\u201362. https:\/\/doi.org\/10.3324\/haematol.2023.282760.","journal-title":"Haematologica"},{"issue":"1","key":"5214_CR82","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021;12(1):2877. https:\/\/doi.org\/10.1038\/s41467-021-22872-z.","journal-title":"Nat Commun"},{"issue":"10","key":"5214_CR83","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1038\/s41375-021-01376-1","volume":"35","author":"R Lewis","year":"2021","unstructured":"Lewis R, Maurer HC, Singh N, Gonzalez-Menendez I, Wirth M, Schick M, et al. CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. Leukemia. 2021;35(10):2895\u2013905. https:\/\/doi.org\/10.1038\/s41375-021-01376-1.","journal-title":"Leukemia"},{"issue":"1","key":"5214_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02502-z","volume":"11","author":"JD Wang","year":"2025","unstructured":"Wang JD, Wang JX, Lin ZL, Xu N, Zhang L, Liu JJ, et al. GPX1 confers resistance to metabolic stress in BCR\/ABL-T315I mutant chronic myeloid leukemia cells. Cell Death Discov. 2025;11(1):229. https:\/\/doi.org\/10.1038\/s41420-025-02502-z.","journal-title":"Cell Death Discov"},{"issue":"1","key":"5214_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01060-y","volume":"14","author":"Z Hong","year":"2021","unstructured":"Hong Z, Wei Z, Xie T, Fu L, Sun J, Zhou F, et al. Targeting chemokines for acute lymphoblastic leukemia therapy. J Hematol Oncol. 2021;14(1):48. https:\/\/doi.org\/10.1186\/s13045-021-01060-y.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"5214_CR86","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1182\/blood.2021013990","volume":"140","author":"Z Chen","year":"2022","unstructured":"Chen Z, Simon-Molas H, Cretenet G, Valle-Argos B, Smith LD, Forconi F, et al. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. Blood. 2022;140(6):630\u201343. https:\/\/doi.org\/10.1182\/blood.2021013990.","journal-title":"Blood"},{"issue":"4","key":"5214_CR87","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/leu.2015.313","volume":"30","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30(4):929\u201336. https:\/\/doi.org\/10.1038\/leu.2015.313.","journal-title":"Leukemia"},{"key":"5214_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1112616","author":"G Benintende","year":"2023","unstructured":"Benintende G, Pozzo F, Innocenti I, Autore F, Fresa A, D\u2019Arena G, et al. Measurable residual disease in chronic lymphocytic leukemia. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1112616.","journal-title":"Front Oncol"},{"issue":"9","key":"5214_CR89","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/13543784.2024.2388567","volume":"33","author":"EA Martino","year":"2024","unstructured":"Martino EA, Bruzzese A, Labanca C, Mendicino F, Lucia E, Olivito V, et al. Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies. Expert Opin Investig Drugs. 2024;33(9):915\u201324. https:\/\/doi.org\/10.1080\/13543784.2024.2388567.","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05214-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05214-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05214-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T02:08:49Z","timestamp":1785982129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05214-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5214"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05214-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a literature review and did not involve human participants, human data, or animal experiment performed by the authors.","order":2,"name":"Ethics","label":"Ethics approval and\u00a0consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1126"}}